Proteomic screening of TMEM43 binding partners identifies VDAC leading to mitochondrial dysfunction
PLOS One · 2025
DOI: 10.1371/journal.pone.0339129 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Qingqing Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Proteomics, Voltage-Dependent Anion Channel 1, Mitochondria, Voltage-Dependent Anion Channel 2. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Planning Program, National Natural Science Foundation of China, Science, Technology and Innovation Commission of Shenzhen Municipality.
Abstract (Originalsprache)
The transmembrane protein 43 (TMEM43) S358L mutation is the most common mutation found in patients with ARVC5, a severe subtype of arrhythmogenic right ventricular cardiomyopathy (ARVC). Characterizing the interacting proteins of TMEM43 mutants is important for unraveling the underlying mechanisms of the relative pathogenesis. Here, we applied quantitative immunoprecipitation (IP)-mass spectrometry (MS) to screen the differential binding partners between TMEM43 and TMEM43 p.S358L and identified 166 interacting protein candidates. Functional enrichment of these proteins highlighted their involvements of calcium signaling, lipid metabolism and cardiovascular diseases. Immunofluorescence (IF) staining and TurboID proximity-labeling further confirmed the interaction of several selected proteins. Moreover, we found that the interaction of both voltage-dependent anion-selective channel proteins (VDAC1 and VDAC2) to TMEM43 mutant significantly decreased. Importantly, lower VDAC binding mediated the mitochondrial dysfunction in cardiac myoblast H9c2 cells of TMEM43 p.S358L. The study provides a comprehensive view of the binding protein landscape of TMEM43 p.S358L, and implies a critical role of TMEM43 in mitochondria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.
- Institute for Advanced Study, Shenzhen University, Shenzhen, Guangdong, China.
- Guangdong Provincial Key Laboratory of Digestive Cancer Research, Guangdong-Hong Kong-Macau University Joint Laboratory of Digestive Cancer Research, Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-…
- School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
ORCID-Profile: Guoxing Zheng, Yingsi Lu, Bo Li
Förderung
- Shenzhen Science and Technology Planning Program
- National Natural Science Foundation of China
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Sun Yat-sen University
Zitieren
APA
Zhu, Q., Zheng, G., Lu, Y., Jiang, Y., Li, Y., Chen, H., Huang, L., Tang, N., Li, B., Lu, Y., Zhang, J., & Zhu, C. (2025). Proteomic screening of TMEM43 binding partners identifies VDAC leading to mitochondrial dysfunction. PLOS One. https://doi.org/10.1371/journal.pone.0339129
Vancouver
Zhu Q, Zheng G, Lu Y, Jiang Y, Li Y, Chen H, et al. Proteomic screening of TMEM43 binding partners identifies VDAC leading to mitochondrial dysfunction. PLOS One. 2025. doi:10.1371/journal.pone.0339129
BibTeX
@article{Zhu2025,
author = {Zhu, Qingqing and Zheng, Guoxing and Lu, Yingsi and Jiang, Yizhou and Li, Yan and Chen, Hong and Huang, Lifen and Tang, Nannan and Li, Bo and Lu, Yi and Zhang, Jian and Zhu, Chengming},
title = {Proteomic screening of TMEM43 binding partners identifies VDAC leading to mitochondrial dysfunction},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0339129}
}
EUVIMED